Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2991-2996

  Vilmar, Adam ^a,b   Santoni Rugiu, Eric ^c   Garcia Focillas, Jesus ^b   Huarriz, Marsisol ^b   Sorensen, Jens Benn ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Rigshospitalet   (Denmark)

Author keywords

Advanced NSCLC; Immunohistochemical analysis; Insulin like growth factor 1 receptor; Methodology; qRT PCR

Indexed keywords

CISPLATIN; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; ADOLESCENT; ADVANCED NSCLC; CANCER STAGING; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; IMMUNOHISTOCHEMICAL ANALYSIS; INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; QRT-PCR; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; YOUNG ADULT;

ADVANCED NSCLC; IMMUNOHISTOCHEMICAL ANALYSIS; INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR; METHODOLOGY; QRT-PCR;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84906313304     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ardizzoni A, Boni L, Tiseo M, Fossella F V, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D and Rosell R: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99(11): 847-857, 2007.
2. Sandler A, Yi J, Hambleton J, Kolb MM and Johnson DH: Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study of bevacizumab (BV) with paclitaxel/carboplatin (PC) for anvanced non-small cell lung cancer. International Associatinon for the Study of Lung Cancer (IALC), Chicago, Illinois. Abstract 133. 2008.
3. Scagliotti G V, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de MF, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21): 3543-3551, 2008.
4. Sorensen J, Hansen O, Vilmar A and Frank H: Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer. J Clin Oncol 27: 15s, (suppl; abstr 8034), 2009.
5. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8): 1227-1234, 2009.
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24): 2542-2550, 2006.
7. Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14(20): 6364-6370, 2008.
8. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K and Yamada O: Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents Med Chem 9(9): 1024-1038, 2009.
9. Sachdev D and Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1): 1-12, 2007.
10. Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28(1): 20-47, 2007.
11. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R and Moorehead RA: Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 26(11): 1636-1644, 2007.
12. Lopez T and Hanahan D: Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1(4): 339-353, 2002.
13. Merrick DT, Dziadziuszko R, Szostakiewicz B, Szymanowska A, Rzyman W, Jassem J, Franklin A, Bunn PA and Hirsch FR: High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (Suppl), 2007: 7550.
14. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA Jr., Varella-Garcia M and Hirsch FR: Insulinlike growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28(13): 2174-2180, 2010.
15. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di CL, Sidoni A, Semeraro A, Del SR, Tofanetti FR, Mameli MG, Daddi G, Cavaliere A, Tonato M and Crino L: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20(5): 842-849, 2009.
16. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Jr., Johnson FM, Green S and Gualberto A: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15): 2516-2522, 2009.
17. Jassem C, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J and Gualberto A: Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC). (abstract) J Clin Oncol s28: 7500, 2010.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247, 2009.
19. Vilmar AC, Santoni-Rugiu E and Sorensen JB: ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21(9): 1817-1824, 2010.
20. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le CT and Soria JC: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991, 2006.
21. Vilmar AC, Santoni-Rugiu E and Sorensen JB: Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17(15): 5205-5214, 2011.
22. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A and Aizawa H: Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98(9): 1336-1343, 2007.
23. Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E and Sorensen JB: RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 75(3): 306-312, 2012.
24. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA and Santoro A. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 21(3): 562-567, 2010.